http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
F. Sinem Hocaoglu-Emre,Devrim Saribal,Guven Yenmis,Guvenc Guvenen 대한내분비학회 2017 Endocrinology and metabolism Vol.32 No.1
Background: Type 2 diabetes mellitus (T2DM) is a multisystemic, chronic disease accompanied by microvascular complicationsinvolving various complicated mechanisms. Intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule 1(VCAM-1), and cluster of differentiation-146 (CD146) are mainly expressed by endothelial cells, and facilitate the adhesion andtransmigration of immune cells, leading to inflammation. In the present study, we evaluated the levels of soluble adhesion moleculesin patients with microvascular complications of T2DM. Methods: Serum and whole blood samples were collected from 58 T2DM patients with microvascular complications and 20 agematchedhealthy subjects. Levels of soluble ICAM-1 (sICAM-1) and soluble VCAM-1 (sVCAM-1) were assessed using enzymelinkedimmunosorbent assay, while flow cytometry was used to determine CD146 levels. Results: Serum sICAM-1 levels were lower in T2DM patients with microvascular complications than in healthy controls (P<0.05). No significant differences were found in sVCAM-1 and CD146 levels between the study and the control group. Although patientswere subdivided into groups according to the type of microvascular complications that they experienced, cell adhesion molecule levelswere not correlated with the complication type. Conclusion: In the study group, most of the patients were on insulin therapy (76%), and 95% of them were receiving angiotensin-convertingenzyme (ACE)-inhibitor agents. Insulin and ACE-inhibitors have been shown to decrease soluble adhesion molecule levels viavarious mechanisms, so we suggest that the decreased or unchanged levels of soluble forms of cellular adhesion molecules in our studygroup may have resulted from insulin and ACE-inhibitor therapy, as well as tissue-localized inflammation in patients with T2DM.